Abstract:Abstract Breast cancer is a complex disease with a high degree of inter-tumor heterogeneity. Subtyping the disease and identifying the genomic features driving these subtypes are critical for precision oncology for breast cancer. With increasing availability of single cell RNA-seq data and deconvolution methods, there is unmet need for identifying novel tumor-intrinsic subtypes based on deconvoluted tumor-specific expression profiles as well as novel bulk tumor subtypes based on bulk RNA-seq data. Drug response prediction based on tumor-intrinsic subtypes can be also potentially more robust than drug response prediction based on bulk subtypes because currently available CRISPR and drug screening data are mostly based on only cancer cell lines. Therefore, we applied consensus hierarchical clustering, Bayesian Non-negative Matrix Factorization (BayesNMF), and deconvolution methods to 1,058 TCGA breast cancer samples and identified seven bulk expression subtypes (S1-S7) and five tumor-specific expression subtypes (S1-S5). In order to characterize our subtypes, we first performed subtype association with previously characterized subtypes, including PAM50, HR status, and METABRIC IntClust subtypes. Notably, Luminal A and METABRIC IntClust 4ER+ breast cancer was further partitioned into our S1 and S5 bulk subtypes. We characterized the subtypes with pathway activity, TME deconvolution, and subtype-associated driver mutations. Our BayesNMF bulk and tumor-specific subtypes showed stronger association with prognosis than PAM50 subtypes, suggesting potential clinical utility of our subtypes. We projected BayesNMF to DepMap cell lines and CPTAC breast cancer samples to identify subtype-specific vulnerabilities and proteogenomic characterization of our subtypes, respectively. We also developed the method to predict CDK4 selective and CDK6 selective drug response in human breast tumor tissues by training the NMF models with CDK4 and CDK6 dependency scores and gene expression features in the DepMap cell lines. Our tumor-specific S5 subtype had significantly lower CDK4 response scores and significantly higher CDK6 response scores than others suggesting that this subtype, which is primarily triple-negative breast cancer, might be potentially a good subtype for CDK6 selective inhibitors. Additionally, our tumor-specific S4 subtype had significantly higher CDK4 response scores and significantly lower CDK6 response scores than others suggesting that this subtype might be a promising patient population for CDK4 selective inhibitors. We further applied machine learning methods to identify biomarkers that associate with subtypes and CDK4/CDK6 dependency scores using gene expression, mutations, and CNAs. Overall, our subtyping approach identifies clinically-relevant novel breast cancer subtypes with subtype-specific cancer vulnerabilities and therapeutic targets. Citation Format: Julie Karam, Paul Rejto, Jadwiga R. Bienkowska, Xinmeng J. Mu, Whijae Roh. Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4543.

Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers

Drug-driven Reclassification of Multiple Tumour Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Molecular classification of hormone receptor-positive HER2-negative breast cancer

Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level

scDrugAtlas: an integrative single-cell drug response atlas for unraveling tumor heterogeneity in therapeutic efficacy

CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response

Abstract 4543: Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

scPharm: identifying pharmacological subpopulations of single cells for precision medicine in cancers

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade